HLscience Co., Ltd.

As of June 30, 2026, HLscience Co., Ltd. carries a market capitalization of 27.15B, placing it among publicly traded companies globally. Its enterprise value stands at 3.13B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, HLscience Co., Ltd. has 5.09M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 2.60, and the price-to-book ratio stands at 0.35.

These figures are as of June 30, 2026. The EV/Sales ratio of 0.30 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 3.13B versus a market cap of 27.15B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, HLscience Co., Ltd. maintains a current ratio of 14.74, meaning it holds 14.7x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, HLscience Co., Ltd. posted a negative return on equity (ROE) of -13.30, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -12.88, reflecting losses generated across the asset base. The company generates approximately 116.97M in revenue per employee across its workforce of 89.25, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.37 indicates how many times HLscience Co., Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, HLscience Co., Ltd. recorded 87.48M in income tax expense. The company reported a pretax loss of -11.13B and -11.15B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 23, 2026, HLscience Co., Ltd.'s stock has declined approximately 44.30% over the past 52 weeks. The 50-day moving average sits at 5,327.40, while the 200-day moving average is 6,686.85.

Over the twelve months ended June 30, 2026, HLscience Co., Ltd. generated 10.44B in revenue and converted that into -11.15B in net income, yielding earnings per share of -2,202.15. EBITDA reached -7.72B, while operating income came in at -10.05B.

These figures are as of June 30, 2026. Total book value stands at 78.24B, with working capital of 27.41B providing operational flexibility.

HLscience Co., Ltd. produced -6.38B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -508.20M in capital expenditures, free cash flow totaled -6.88B - equivalent to -1,351.41 per share.

Over the twelve months ended June 30, 2026, HLscience Co., Ltd. posted a gross margin of 31.53, reflecting its pricing power and cost economics. The operating margin of -96.28 and net profit margin of -106.83 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -25.35: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -0.04, meaning HLscience Co., Ltd. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

HLscience Co., Ltd.'s most recent stock split took place on December 29, 2020 with a 20:21 split ratio.

As of June 30, 2026, HLscience Co., Ltd. has an Altman Z-Score of 8.48, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.